BioNote

BioNote EPS CAGR 5Y

EPS CAGR (5 Year) of BioNote (377740.KS) as of Oct 18, 2026.

EPS CAGR 5Y

-

Last updated:

EPS CAGR (5 Year) of BioNote is 2026 - . EPS CAGR (5 Year) of BioNote was 2025 22.42 % . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioNote Stock analysis

What does BioNote do? BioNote Inc., headquartered in Hwaseong, South Korea, operates in the Health Care sector, specifically within Biotechnology. The company develops and manufactures rapid diagnostic kits for humans and animals, including immunochemical and fluorescence-based diagnostic products. It also produces raw materials such as antigens, antibodies, and enzymes, along with semi-finished products for diagnostic use. Listed on December 22, 2022, BioNote focuses on veterinary and human diagnostic solutions. BioNote is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioNote stock

On Eulerpool you can find the complete historical development of EPS CAGR (5 Year) BioNote since 2006 – with annual values, charts, and detailed analysis.

The 5-year EPS CAGR measures compound per-share earnings growth over five years, providing a medium-term view of shareholder value creation.

To evaluate EPS CAGR (5 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EPS CAGR (5 Year).

EPS CAGR (5 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EPS CAGR (5 Year)'s BioNote historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — BioNote

All Key Metrics — BioNote